Outsized Ventures

Magdrive Limited, established in 2019 and headquartered in Didcot, United Kingdom, specializes in developing advanced spacecraft propulsion systems tailored for small satellites. The company's innovative technology features a plasma thruster that combines the high thrust of chemical rockets with the high efficiency of electric thrusters. This dual capability allows spacecraft to travel faster and longer while reducing propellant requirements, thereby lowering costs and improving fuel efficiency for satellite maneuvers and missions in Low Earth Orbit (LEO).

Biorce is a pioneering HealthAI startup dedicated to revolutionizing drug development via artificial intelligence. The company's core product is a clinical AI assistant, designed to streamline clinical trials, enhancing both speed and cost efficiency. This platform grants access to clinical data, empowering researchers to accelerate medical advancements and ultimately improve patient outcomes.

MixRift is a gaming company specializing in designing and developing interactive mixed-reality gaming experiences. It offers survival and puzzle games, aiming to provide immersive entertainment that bridges the gap between virtual and real-world gaming.

Julienne Bruno is a producer of plant-based foods that uses naturally plant-based ingredients such as fermented legumes and slow-roasted vegetables to create dairy-free and meat-free products, including cheese and salami-based items. The company aims to offer new, nutritious plant-based alternatives that enable customers to enjoy a variety of dishes without animal products.

Founded in London in 2019, Emitwise develops software that empowers businesses to automatically measure, report, and reduce their carbon footprint across operations and supply chain. Its AI-driven solution, Emitwise, enables real-time tracking of emissions, facilitating data-driven decisions for sustainability targets.

Molecule.one is a biotechnology company that specializes in artificial intelligence-driven software for chemical synthesis. Its m1 platform enhances the preclinical pipeline by maximizing efficiency in chemistry-related processes. The company’s software predicts the likelihood of synthesizing novel small molecules and automates significant portions of the manual work involved in synthesis design. By leveraging vast datasets that exceed human processing capabilities, Molecule.one enables clients to concentrate on drug candidates that are not only cost-effective to synthesize but also have a higher probability of success in the development process. This integration of AI into chemical synthesis represents a significant advancement in the field, streamlining workflows for bench chemists, data scientists, and computational chemists alike.

Treos Bio, Inc. is a clinical-stage biotechnology company focused on developing precision cancer immunotherapies that are tailored to individual patients' genetic profiles. Founded in 2013 and headquartered in San Francisco, California, Treos Bio employs advanced computational data science and proprietary biomarkers to create targeted immunotherapies. Its product offerings include the PEPI test, which analyzes genetic data from saliva or blood samples to predict a person’s immune response to specific antigens. The company also produces PolyPEPI immunotherapy vaccines designed for various cancers, including melanoma, lung, breast, colorectal, ovarian, glioma, and leukemia. Additionally, Treos Bio offers the PolyPEPI CDx companion diagnostic test to determine the effectiveness of treatments for individual patients, as well as a Melanoma Screening Test that identifies individuals at high risk for melanoma based on genetic information.

Hoxton Farms, based in London, UK, specializes in producing real animal fat without the use of animals. The company employs cell biology and advanced mathematical modeling to cultivate purified animal fat in bioreactors, catering primarily to the meat alternatives industry. This innovative approach enables the creation of cruelty-free fat that can be utilized not only in meat alternatives but also in other sectors such as bakery, confectionery, and cosmetics. By focusing on sustainable and ethical production methods, Hoxton Farms aims to transform the way fat is sourced and used in various products.

Magdrive Limited, established in 2019 and headquartered in Didcot, United Kingdom, specializes in developing advanced spacecraft propulsion systems tailored for small satellites. The company's innovative technology features a plasma thruster that combines the high thrust of chemical rockets with the high efficiency of electric thrusters. This dual capability allows spacecraft to travel faster and longer while reducing propellant requirements, thereby lowering costs and improving fuel efficiency for satellite maneuvers and missions in Low Earth Orbit (LEO).

Living Optics designs and develops a compact hyperspectral imaging camera and accompanying software to provide spectral imaging data across industrial, consumer, medical, and manufacturing applications. The system captures information beyond the capabilities of ordinary cameras, delivering accessible, portable hyperspectral imaging for use in research and product development. The company was founded in 2019 and is based in Oxford, United Kingdom.

Hoxton Farms, based in London, UK, specializes in producing real animal fat without the use of animals. The company employs cell biology and advanced mathematical modeling to cultivate purified animal fat in bioreactors, catering primarily to the meat alternatives industry. This innovative approach enables the creation of cruelty-free fat that can be utilized not only in meat alternatives but also in other sectors such as bakery, confectionery, and cosmetics. By focusing on sustainable and ethical production methods, Hoxton Farms aims to transform the way fat is sourced and used in various products.

Kernal Biologics, Inc. is a biotechnology company focused on designing and developing mRNA immunotherapies aimed at treating diseases such as COVID-19 and various cancers. Founded in 2016 and headquartered in Cambridge, Massachusetts, the company leverages its mRNA platform to enable researchers and organizations to create vaccines and therapeutics. Kernal’s innovative approach allows specific cells to produce their own therapeutic agents. With a team that has strong connections to prestigious institutions like MIT and Harvard, as well as experience in the pharmaceutical industry, Kernal Biologics has garnered recognition for its work, winning multiple awards from notable organizations, including Amgen and NASA.

Biomage is a company dedicated to advancing life sciences through innovative single-cell analysis. It offers a platform that enables researchers to analyze vast single-cell sequencing data efficiently, transforming complex biological data into actionable insights. This capability supports both academic and industrial scientists in enhancing drug target discovery while reducing costs. The Biomage Single Cell Platform allows users to manage their single-cell data analysis with ease, providing deep biological insights in a streamlined manner. By applying advanced computational methods, Biomage is at the forefront of facilitating groundbreaking research across various biological disciplines.

Fathom Radiant was created on the premise of applying first-principles thinking to create technology capable of enabling artificial general intelligence for the benefit of all. The company does not believe that the beneficial advancement of AI is unavoidable, and Faathom believes that as a company offering a critical layer in the AI technology stack, we can make a difference in how securely advanced AI systems are built and deployed.

Founded in 2017, Phenomic AI is a Toronto-based company that develops artificial intelligence-driven drug discovery platforms. Its technology analyzes phenotypes in complex disease models like high-content co-culture and 3D assays, enabling pharmaceutical companies to discover drugs more efficiently.

Mahana Therapeutics, Inc. is a company focused on developing digital treatments for individuals with chronic health conditions, particularly gastrointestinal diseases. Its flagship offering, Parallel, is a clinically validated, minimal-contact digital program specifically designed for patients suffering from irritable bowel syndrome (IBS). The program aims to deliver both physical and psychological support to enhance patient well-being. Founded in 2018 and headquartered in San Francisco, California, Mahana Therapeutics also maintains an office in London, United Kingdom. The company was previously known as Mahana Health, Inc. before rebranding in July 2019.

Temporall is a developer of an AI-driven workplace intelligence platform that assists organizations in enhancing their effectiveness. By aggregating and connecting fragmented data across a company, Temporall employs artificial intelligence and machine learning techniques to analyze this information and extract valuable insights. The platform is designed to support leadership teams by offering expert recommendations and comprehensive reporting, ultimately guiding clients toward performance optimization. Positioned at the intersection of enterprise software and organizational science, Temporall combines advanced technology with human expertise to address the strategic needs of its clients.